Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the validation of its ARM vaccine candidate in a melanoma model with a cure rate of 60%.
Read MoreAmgen, one of the world’s leading biotechnology companies, and Mila – Quebec Artificial Intelligence Institute, are expanding their partnership aimed at further transforming Artificial Intelligence (AI) guided drug development. As part of this evolution, Amgen is establishing a corporate laboratory within Mila’s headquarters where scientists from both organizations will interact and engage.
Read MoreThe Honourable Pablo Rodriguez, Minister of Canadian Heritage and Quebec Lieutenant, today announced, on behalf of the Honourable Pascale St–Onge, Minister of Sport and Minister responsible for Canada Economic Development for Quebec Regions (CED), a repayable contribution of $600,000 for CIRION BioPharma Research Inc.
Read MoreThe Canadian Alliance for Skills and Training in Life Sciences (CASTL) announced its expansion into Quebec with the location of their future Biomanufacturing Training Facility in Montreal.
Read MoreGiiant Pharma Inc., a Canadian, preclinical-stage biotech company, today announced that the Company will receive financial support from the US Crohn’s and Colitis Foundation, through its IBD Ventures program, for an amount up to US$ 500,000.
Read MoreDomain Therapeutics, a drug discovery and development company focused on G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today announces that the first patient has been dosed with DT-9081, Domain’s proprietary IO asset, in a first-in-human Phase I study.
Read MoreAbCellera announced today that it has entered into a multi-year, multi-target strategic collaboration with AbbVie Inc. The partnership will leverage AbCellera’s antibody discovery and development engine to deliver optimized development candidates for up to five targets selected by AbbVie across multiple indications.
Read MoreIMV Inc. today announced positive initial patient data from the VITALIZE Phase 2B trial evaluating its lead DPX product, MVP-S, in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma (“r/r DLBCL”) who received at least three previous lines of treatment.
Read MoreOn December 10th, 2021, BIOQuébec and other players in the life sciences industry in Quebec sent several federal elected officials their serious concerns regarding the coming into force of the PMPRB reform. As leading representatives of the Quebec life sciences sector who actively and strategically contribute to the country's economy, they asked that the implementation of the PMPRB reform be suspended. A year later, on December 5th, 2022, new developments compel Montréal InVivo, Sherbrooke Innopole and BIOQuébec to reiterate this request. A new request for the postponement of the coming into force of new guidelines has therefore been formulated as part of the PMPRB's consultation process.
Read MoreDefence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the successful completion of all GLP studies related to its anti-cancer treatment, AccuTOX.
Read MoreDomain Therapeutics, a drug discovery and development company focused on G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today announces the appointments of Professor Antoine Italiano and Professor John Stagg to its Scientific Advisory Board (SAB).
Read MoreMONTREAL (CANADA) – November 29, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that the first patient has been dosed with INV-202 in a Phase 2 clinical trial in subjects with diabetic kidney disease (DKD).
Read MoreOur executive director, Emmanuelle Toussaint, at BIOQuébec had the honor of participating to the “Rendez-Vous Politique de la Fédération des chambres de commerce du Québec (FCCQ)” with Canada’s Minister of Health, Jean-Yves Duclos
Read MoreQuebec is rich in innovative companies that strive to do things differently to bring our knowledge and skills to another level. We were delighted to honor our members Jenthera Therapeutics, Repare Therapeutics, Ventus Therapeutics, KisoJi Biotechnology, Valence Discovery and Modelis who all innovate in the field of life sciences for the development of new therapies.
Read MoreBIOquébec is proud to announce the winner of the Gala des Prix Innovation 2022 in the "Life Sciences" category: Innodal ! We are delighted to have such an innovative company among our members, that is innovating with a new generation of antimicrobials to improve food safety standards and meets the consumer’s demands. The ’’Prix Coup de Cœur ‘’ goes to Paperplane Therapeutics who designs therapeutic virtual reality video games aimed at improving pain and anxiety management in children undergoing various medical treatments or procedures. Congratulations to the finalists Ditch Labs and KAT Innovation.
Read MoreOn behalf of the member companies of the biotechnology and life sciences organizations across Canada, we are writing on this occasion to urge the government to oppose the TRIPS waivers proposal before the World Trade Organization which would allow countries to force the transfer of intellectual property and know-how on covid-19 vaccines. The proposed waiver fundamentally undermines the very system that produced the current group of COVID-19 vaccines and will be a disincentive for the investors and companies taking risks to develop solutions for the next health emergency.
Read MoreAs everybody knows by now, words matter in politics as well as in science. Here is a brief account of how this new focus came about and how it led up to a new thematic series now fully published in Life Sciences, Society and Policy.
Read MoreScheduled to visit from November 26 to 30, the delegation will travel to the cities of Bengaluru and Mumbai. The focus of this visit is the Information and Communication Technology (ICT) and life sciences industry.
Read MoreBIOQuébec welcomed the Québec government’s life sciences strategy which was unveiled earlier today, the contents of which will support the creation of value generated by the biotechnology and life sciences industry.
Read More
